Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(8 sites)

United States

Mayo Clinic, Scottsdale, Arizona

UCSF Medical Center, San Francisco, California

Stanford Medical Center, Stanford, California

University of Colorado, Aurora, Colorado

Northwestern University, Chicago, Illinois

Tufts University, Boston, Massachusetts

Massachusetts General Hospital, Boston, Massachusetts

Brigham and Women's Hospital, Boston, Massachusetts